Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen receptor axis have significantly delayed disease progression. However, drug ...

The approval of 3 androgen receptor pathway inhibitors (ARPIs) has given providers novel treatment options for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) that have ...

But of course, the last few years, really the last decade to decade and a half, has been the advent of what we call, now call ARPIs, or androgen receptor pathway inhibitors. And these are really ...

Androgen receptor pathway inhibitors were shown to better treat patients with metastatic castration-resistant prostate cancer and improved survival. A certain type of inhibitor has shown potential in ...

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why ...

Barriers to adopting androgen receptor pathway inhibitors (ARPIs) in metastatic hormone-sensitive prostate cancer (mHSPC) treatment include cost, physician awareness, patient education, and ...

PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage i ...

Androgen Receptor Pathway in Salivary Gland Cancer. Alan L. Ho Journal of Clinical Oncology 2021 39: 36, 4069-4072. View Options. Login options. Check and see if you have full access through your ...

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3 ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...